The decision to place an arterial catheter for monitoring purposes was made by the attending medical staff without reference to this study. Patency of the catheter was maintained with an infusion of 5% dextrose containing 1 U/ml heparin at a rate of 1 ml/hour. All flushing solutions were heparin free. Apart from the administration of 24 U/day heparin, no study patient received anticoagulant or thrombolytic drugs. Vitamin K (0-5-1 0 mg) was given parenterally at birth to all infants. Administration of blood products during the six hours preceding the study sample was recorded in all subjects.
Subjects and methods

SUBJECTS
The study was conducted in the neonatal intensive care unit at McMaster University between April 1989 and March 1990. All infants admitted to the unit were eligible for enrolment if the following two criteria were met: (i) postnatal age less than 36 hours and (ii) indwelling arterial catheter with undampened pressure tracing. The latter ensured recruitment of the group of patients in the nursery who were most ill and also allowed artifact free blood sampling. The study was approved by the Institutional Review Board for research involving human subjects.
The decision to place an arterial catheter for monitoring purposes was made by the attending medical staff without reference to this study. Patency of the catheter was maintained with an infusion of 5% dextrose containing 1 U/ml heparin at a rate of 1 ml/hour. All Table 2 gives the observed frequencies of abnormal tests together with the 95% confidence intervals. Of the 47 infants with abnormal plasma coagulation, 18 patients had an increased INR, whereas 16 subjects had a low fibrinogen concentration. In a further 13 infants the two tests were abnormal. Among infants with an abnormal INR, the median value was [1] [2] [3] [4] [5] [6] [7] (maximum 3.1). Among infants with hypofibrinogenaemia the median fibrinogen concentration was 1.1 g/l (minimum 03 g/l). The median platelet count in the 36 infants with thrombocytopenia was 118x109/l (minimum 36x109/l).
PREDICTION OF COAGULOPATHY Table 3 summarises the sensitivities, specificities, predictive values, and likelihood ratios for all examined risk factors of coagulopathy.
Discussion
Abnormalities of the coagulation system are reported to be common in ill neonates, yet little is known about the prevalence of plasma clotting defects in unselected high risk infants. In this prospective cohort study coagulation screening tests were abnormal within the first 36 hours in about one third of all infants who were sick enough to require an indwelling arterial catheter for monitoring purposes. Abnormalities of plasma coagulation could not be predicted accurately by more readily known risk factors such as immaturity, fetal growth retardation, or poor Apgar scores. The strongest predictor of coagulopathy was thrombocytopenia. Infants with platelet counts <150x109/l were 3-7 times more likely to have plasma coagulation defects than infants with normal platelet counts. Further, normal INR and fibrinogen values were less than half as likely to be found in infants weighing <1500 g than in larger infants. Low birth weight, however, was not a strong predictor of abnormal plasma coagulation. Thus our data suggest that screening for coagulopathy will have the highest yield in infants with early thrombocytopenia whereas infants with birth weights >1500 g are least likely to have laboratory evidence of coagulopathy.
The clinical significance of abnormal coagulation screening tests is currently uncertain. Although no infant was noted to bleed overtly at the time of the study, occult haemorrhage may well have contributed to the morbidity of these critically ill infants. This hypothesis is supported by previous descriptions of an association between abnormal coagulation tests and the presence and severity of intracranial haemorrhage in preterm infants.7-10 Trials of fresh frozen plasma or other preparations of coagulation factors in the prevention of intracranial haemorrhage have yielded conflicting results.1' Further studies are therefore required to determine whether sick newborn infants would benefit from the detection and correction of clinically inapparent clotting defects. 
